FO
AERI

FT Options’s Aerie Pharmaceuticals AERI Stock Holding History

FT Options’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$17K Buy
+16,000
New +$873K 0.03% 173
2016
Q4 		– Sell
-14,900
Closed -$177K – 409
2016
Q3 		$177K Buy
+14,900
New +$329K 0.14% 111

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FT Options's AERI Position: Q3 2017 in Review

FT Options increased its Aerie Pharmaceuticals (AERI) stake by 16% in Q3 2017, buying an estimated $37.4K and bringing the position to 5,060 shares worth $246K. The position accounts for 0.37% of the portfolio, ranked #58.

FT Options first reported a position in AERI in Q1 2016 and has held it in 4 quarters since. The position peaked at $628K in Q3 2016. 182 funds tracked by Wall St. Rank hold AERI as of Q3 2017.

  • FT Options held 5,060 shares of Aerie Pharmaceuticals worth $246K as of Q3 2017.
  • FT Options bought 685 Aerie Pharmaceuticals shares in Q3 2017, an estimated $37.4K.
  • Aerie Pharmaceuticals made up 0.37% of FT Options's portfolio in Q3 2017, its #58 holding.
  • FT Options first reported a position in Aerie Pharmaceuticals in Q1 2016 and has held it in 4 quarters since.
  • FT Options's Aerie Pharmaceuticals position peaked at $628K in Q3 2016.
  • 182 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.